A policy intent described in less than 100 words with a price tag of $500,000 has evolved into what is now Australia's vast and sprawling HTA institutional decision-making structure.
Was this 'vast and sprawling' industry ever the intention?
February 23, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Medicines Australia chief says next negotiation is about getting comfortable with being uncomfortable
July 3, 2026 - - Latest News -
New once weekly therapy offers extended protection for people with haemophilia A
July 3, 2026 - - Latest News -
Nurse prescribing reform set to expand access to PBS subsidised medicines
July 3, 2026 - - Latest News -
Nothing else grows below this self-serving and broken institutional framework
July 3, 2026 - - Latest News -
Minister looks to be sending a very clear message about these therapies and the PBS
July 2, 2026 - - Latest News -
Cartherics emerges as Asia Pacific leader in off-the-shelf immune cell therapy
July 2, 2026 - - Australian Biotech -
The end-game of strong-arming companies over prices at the expense of patients and process
July 2, 2026 - - Latest News

